Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Galectin Therapeutics Inc.


Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq: GALT), if they purchased the Company’s securities during the period between January 6, 2014 and July 28, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Nevada.

What You May Do

If you purchased shares of Galectin and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 29, 2014.

About the Lawsuit

Galectin and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.

On July 24, 2014, Emerging Growth Corp. issued a press release touting Galectin and stating that Galectin was "nipping at [the] heels" of its competitors. Then, on July 28, 2014, an article on claimed that Galectin had "strong ties to stock promoters" engaging in a misleading campaign aimed at boosting its stock price, and an article on revealed that Emerging Growth was the investor relations and marketing company Galectin was paying for misleading promotional campaigns to entice investors to buy its stock.

On this news, the value of Galectin’s stock plummeted by 61%.

About Kahn Swick & Foti, LLC

To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit

Rate this press release
3 stars


Add to favourites icon Add to favourites